ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis

Ding, Huanyu; Jiang, Minchun; Lau, Chi Wai; Luo, Jianfang; Chan, Andrew M. M.; Wang, Li*; Huang, Yu*广东省人民医院; 广东省心血管病研究所; y
British Journal of Pharmacology2023-4DOI: 10.1111/bph.16007
1被引8阅读
引用收藏
分享

摘要

Background and PurposeAtherosclerotic vascular disease is the leading cause of mortality and morbidity worldwide. Our previous study uncovered that endothelium-specific knockdown of YAP suppresses atherogenesis, suggesting that YAP is a promising therapeutic target against atherosclerotic vascular disease. We established a drug screening platform, which aimed to identify new YAP inhibitors for anti-atherosclerotic treatment. Experimental ApproachDrug screening was performed by a luciferase reporter gene assay. RNA sequencing was performed to acquire the transcriptomic profile of CBL0137-treated endothelial cells. We assessed and validated the inhibitory effect of CBL0137 on YAP activity and inflammatory response in HUVECs and HAECs. We evaluated the vasoprotective effect of CBL0137 in vivo against plaque formation in ApoE(-/-) mice, using both disturbed flow-induced and chronic western diet-induced atherosclerotic models. Key ResultsWe identified CBL0137 as a novel YAP inhibitor from an FDA drug library. CBL0137 inhibited YAP activity by restraining its phosphorylation at Y357. CBL0137 inhibited YAP activity to repress endothelial inflammation. Mechanistically, CBL0137 suppressed YAP phosphorylation at Y357 via the tyrosine-protein kinase Src. Furthermore, administration of CBL0137 ameliorated endothelial inflammation and the atherogenesis induced by disturbed flow and consumption of an atherogenic diet in ApoE(-/-) mice. Conclusion and ImplicationsTo our knowledge, this is the first study to identify CBL0137 as a novel YAP inhibitor. We have demonstrated that pharmacologically targeting YAP by CBL0137 inhibits atherogenesis. The present results suggest that CBL0137 holds promise as a new drug for the treatment of atherosclerotic vascular disease.

学科与关键词

关键词
atherosclerosisCBL0137endothelial inflammationSrcYAP
相关
加载中…
  • Thioridazine protects against disturbed flow-induced atherosclerosis by inhibiting RhoA/YAP-mediated endothelial inflammation
    Jiang, Min-chun; Ding, Huan-yu; Huang, Yu-hong; Cheng, Chak Kwong; Lau, Chi Wai; Xia, Yin; Yao, Xiao-qiang; Wang, Li; Huang, YuActa Pharmacologica Sinica, 2023, 44(10): 1977-1988.被引 1
  • Deletion of BACH1 Attenuates Atherosclerosis by Reducing Endothelial Inflammation
    Jia, Mengping; Li, Qinhan; Guo, Jieyu; Shi, Weihao; Zhu, Lei; Huang, Yijun; Li, Yongbo; Wang, Li; Ma, Siyu; Zhuang, Tao; Wang, Xiaoqun; Pan, Qi; Wei, Xiangxiang; Qin, Yue; Li, Xiaobo; Jin, Jiayu; Zhi, Xiuling; Tang, Jingdong; Jing, Qing; Li, Shanqun; Jiang, Lindi; Qu, Lefeng; Osto, Elena; Zhang, Jianyi; Wang, Xinhong*; Yu, Bo*; Meng, Dan*Circulation Research, 2022, 130(7): 1038-1055.被引 48
  • YAP accelerates vascular senescence via blocking autophagic flux and activating mTOR
    Pan, Xianmei; Wu, Bo; Fan, Xianglin; Xu, Guanghui; Ou, Caiwen*; Chen, Minsheng*Journal of Cellular and Molecular Medicine, 2021, 25(1): 170-183.被引 21
查看全部 →

发表信息

论文状态
公开发表
期刊
British Journal of Pharmacology
发表日期
2023-04
卷期
第 180 卷, 第 8 期
页码
1168-1185
DOI
10.1111/bph.16007
语言
ENGLISH
成果收录
SCIE
资助标注
Hong Kong Research Grants Council [14109618, 14164817, C4024-16W, SRFS2021-4S04]; Hong Kong PhD Fellowship Scheme; Natural Science Foundation of China [91939302]; Health and Medical Research Fund [07181286]

作者

  • D

    Ding, Huanyu (第一作者)

    chinese univ hong kong

  • J

    Jiang, Minchun

    chinese univ hong kong

查看全部 7 位作者收起作者
  • L

    Lau, Chi Wai

    chinese univ hong kong

  • L

    Luo, Jianfang

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • C

    Chan, Andrew M. M.

    chinese univ hong kong

  • W

    Wang, Li (通讯)

  • H

    Huang, Yu (通讯)

    chinese univ hong kong

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417